The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Aug. 23, 2021
Applicant:

Sorrento Therapeutics, Inc., San Diego, CA (US);

Inventor:

Min Soo Kim, San Diego, CA (US);

Assignee:

SORRENTO THERAPEUTICS, INC., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); G01N 33/53 (2006.01); C07K 16/28 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); G01N 33/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.


Find Patent Forward Citations

Loading…